본문으로 건너뛰기
← 뒤로

Burden and Clinical Impact of Hepatitis D Virus Co-Infection Among HBsAg-Positive Patients in Mauritania.

1/5 보강
Diseases (Basel, Switzerland) 📖 저널 OA 100% 2022: 2/2 OA 2024: 8/8 OA 2025: 24/24 OA 2026: 15/15 OA 2022~2026 2026 Vol.14(2)
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
환자: HDV infection frequently exhibited suppressed HBV DNA levels, reflecting viral interference
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
HDV co-infection is the principal driver of severe liver disease, often occurring despite low or undetectable HBV DNA levels. Systematic HDV screening among all HBsAg-positive individuals is urgently needed to improve risk stratification, guide therapeutic decisions, and reduce liver-related morbidity and mortality.

Abdawa M, Hemeyine M, Chemin I, Lunel-Fabiani F, Mohamed Abdellahi MV

📝 환자 설명용 한 줄

[BACKGROUND] Hepatitis B virus (HBV) infection remains highly endemic in sub-Saharan Africa, where hepatitis delta virus (HDV) co-infection substantially worsens liver disease outcomes.

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 연구 설계 cross-sectional

이 논문을 인용하기

↓ .bib ↓ .ris
APA Abdawa M, Hemeyine M, et al. (2026). Burden and Clinical Impact of Hepatitis D Virus Co-Infection Among HBsAg-Positive Patients in Mauritania.. Diseases (Basel, Switzerland), 14(2). https://doi.org/10.3390/diseases14020069
MLA Abdawa M, et al.. "Burden and Clinical Impact of Hepatitis D Virus Co-Infection Among HBsAg-Positive Patients in Mauritania.." Diseases (Basel, Switzerland), vol. 14, no. 2, 2026.
PMID 41745107 ↗

Abstract

[BACKGROUND] Hepatitis B virus (HBV) infection remains highly endemic in sub-Saharan Africa, where hepatitis delta virus (HDV) co-infection substantially worsens liver disease outcomes. Mauritania has long been suspected to be a high-burden setting for HBV-HDV co-infection, yet contemporary data describing its clinical and virological impact remain limited.

[METHODS] We conducted a hospital-based cross-sectional study at the National Institute of Hepato-Virology (INHV) in Nouakchott, including 401 HBsAg-positive patients. Demographic, clinical, biological, and virological data were collected. HDV serology and RNA testing were performed when available. Liver disease severity, including cirrhosis and hepatocellular carcinoma (HCC), was assessed using clinical, biological, and imaging criteria.

[RESULTS] HDV antibodies were detected in 31.9% of HBsAg-positive patients, confirming Mauritania as a hyper-endemic area for HDV. HDV co-infection was strongly associated with advanced liver disease, with HDV antibodies present in 86.4% of cirrhotic patients and 82.4% of those with HCC. Patients with HDV infection frequently exhibited suppressed HBV DNA levels, reflecting viral interference. A substantial proportion of patients presented with decompensated cirrhosis or HCC at diagnosis, and nearly 70% were treatment-naïve. Overall, HDV co-infection emerged as the principal driver of severe liver disease in this cohort.

[CONCLUSIONS] HBV/HDV co-infection is highly prevalent in Mauritania and is associated with a wide clinical spectrum ranging from asymptomatic infection to decompensated cirrhosis and hepatocellular carcinoma. HDV co-infection is the principal driver of severe liver disease, often occurring despite low or undetectable HBV DNA levels. Systematic HDV screening among all HBsAg-positive individuals is urgently needed to improve risk stratification, guide therapeutic decisions, and reduce liver-related morbidity and mortality.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기